-
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners July 12, 2026 11:18 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data…
-
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
July 07, 2026 09:12 ET | Source: Alamar Biosciences, Inc. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program…
-
Zydus Hospital, Ahmedabad sets a new dimension in Alzheimer testing
A simple blood test can now detect AD early, boosting quality of life AHMEDABAD, India, June 19, 2026 /PRNewswire/ — As people grow older, changes occur in all parts of the body, including the brain. Forgetfulness can be a normal part of aging. Alzheimer’s disease (AD) is the most common type of dementia and can be…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
